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Abstract: Low residual renal function (RRF) and serumbicarbonate are
associated with adverse outcomes in peritoneal dialysis (PD) patients.
However, a relationship between the 2 has not yet been determined in
these patients. Therefore, this study aimed to investigate whether low
serum bicarbonate has a deteriorating effect on RRF in PD patients.
This prospective observational study included a total of 405 incident
patients who started PD between January 2000 and December 2005. We
determined risk factors for complete loss of RRF using competing risk
methods and evaluated the effects of time-averaged serum bicarbonate
(TA-Bic) on the decline of RRF over the first 3 years of dialysis treatment
using generalized linear mixed models.
During thefirst3yearsofdialysis, 95 (23.5%)patientsbecameanuric.The
mean time until patients became anuric was 20.8 9.0 months. After
adjusting for multiple potentially confounding covariates, an increase in
TA-Bic level was associated with a significantly decreased risk of loss of
RRF (hazard ratio per 1mEq/L increase, 0.84; 0.75–0.93; P¼ 0.002), and in
comparison to TA-Bic 24mEq/L, TA-Bic< 24mEq/L conferred a 2.62-
fold higher risk of becoming anuric. Furthermore, the rate of RRF decline
estimated by generalized linear mixed models was significantly greater in
patients with TA-Bic< 24mEq/L compared with those with TA-
Bic 24mEq/L (0.16 vs 0.11mL/min/mo/1.73m2, P< 0.001).
In this study, a clear association was found between low serum
bicarbonate and loss of RRF in PD patients. Nevertheless, whetheri, MD, PhD, Dae PhD,
Han, MD, PhD
(Medicine 94(31):e1276)
Abbreviations: %LBM = percentage of lean body mass, BMI =
body mass index, CI = confidence interval, CKD = chronic kidney
disease, CRP = C-reactive protein, ESRD = end-stage renal disease,
GFR = glomerular filtration rate, HD = hemodialysis, HR = hazard
ratio, nPCR = normalized protein catabolic rate, PD = peritoneal
dialysis, RRF = residual renal function, TA-Bic = time-averaged
serum bicarbonate.
INTRODUCTION
D ecline of residual renal function (RRF) is an independentrisk factor for adverse outcomes in patients with chronic
kidney disease (CKD), and remains important even after dialy-
sis has been started.1–3 It is associated with fluid overload,4
anemia,5 inflammation,6 and malnutrition,7 and is also a strong
predictor of mortality in these patients.8–10 Thus, preserving
RRF is now considered to be one of the primary goals in
managing patients on dialysis.
Recently, metabolic acidosis, which usually manifests as
low serum bicarbonate, has emerged as a modifiable factor that
is strongly associated with increased mortality in CKD
patients.11–16 Correction of acidosis confers kidney protection
and also slows glomerular filtration rate (GFR) decline in
nondialysis-dependent CKD patients.17–24 This considerable
evidence has raised the possibility that low serum bicarbonate
levels may be associated with rapid decline or complete loss of
RRF, and can thereby contribute to poor outcomes in peritoneal
dialysis (PD) patients. Nevertheless, there are only a few studies
that have investigated whether low serum bicarbonate predicts,
or has a deteriorating effect on RRF in these patients. Therefore,
the purpose of this study was to determine the associations
between low serum bicarbonate and loss of RRF in a large
prospective cohort of incident patients undergoing PD.
METHODS
Patients
The study population included 549 end-stage renal disease
(ESRD) patients who started PD at Yonsei University Severance
Hospital or NHIS Ilsan Hospital between January 2000 and
December 2005. Exclusion criteria were <18 years of age at
initiation of PD, <3 RRF measurements, prior history of
hemodialysis (HD) or a kidney transplant before PD was
initiated, recovery of kidney function, or initiation of PD for
other reasons such as acute renal failure or congestive heartere interested in the decline of RRF,
luded when they were already anuric at
erefore, this prospective observational
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Chang et alstudy included a total of 405 incident patients (Figure 1). The
study was carried out in accordance with the Declaration of
Helsinki and approved by the Institutional Review Board of
Ilsan Hospital Clinical Trial Center. We obtained informed
written consent from all participants involved in our study.
Data Collection
Demographic and clinical data were collected at the begin-
ning of PD. These included age, sex, body mass index (BMI)
calculated as weight/(height),2 cause of ESRD, presence of
diabetes, and medications. Charlson Comorbidity Index was
scored at the start of PD which was a scoring system that
includes weighing factors on important concomitant diseases.25
Data on RRF were collected within 3 months of PD
initiation and followed by 6-month intervals thereafter. RRF
was expressed as residual GFR, calculated as the average urea,
and creatinine clearance from a 24-hour urine collection.26
Residual GFR was considered null when urine output was
<200mL/d. When a patient reached a residual GFR below this
level at 2 successive time points, we defined the patient as anuric
from the first time point of the 2 measurements.
Laboratory and dialysis characteristics obtained at the time
of initial dialysis adequacy measurement were considered as
baseline values, and included serum bicarbonate concentrations,
blood urea nitrogen, serum creatinine, total cholesterol, calcium,
phosphorus, serum albumin, serum C-reactive protein (CRP)
levels, Kt/Vurea, dialysis volume, PD ultrafiltration, normalized
protein catabolic rate (nPCR), percentage of lean body mass
(%LBM), and types of dialysate. Serum total CO2, which is
generally used as an indirect measure of serum bicarbonate
concentration,27 was measured by an electrode-based method
(UniCel DXC 800; Beckman Coulter, Inc, CA) and recorded
longitudinally throughout the follow-up period. Time-averaged
serum bicarbonate (TA-Bic) was calculated as an average of the
mean of bicarbonate measurements every 3 months.
Statistical Analysis
All values are expressed as the mean standard deviation
or percentages. Statistical analyses were performed using SAS
FIGURE 1. Flow chart of participants in the cohort. HD¼hemo-
dialysis, KT¼ kidney transplant, PD¼peritoneal dialysis, RRF¼
residual renal function.version 9.2.3 (SAS Institute Inc, Cary, NC) and the software
package R version 3.0.2. Comparisons were made by Student t
test for continuous variables and by the x2 test for categorical
2 | www.md-journal.comvariables as required. The Kolmogorov–Smirnov test was used
to determine the normality of the distribution of parameters. If
data did not show a normal distribution, they were expressed as
the median and interquartile range (or after log-transformation),
and were compared using the Mann–Whitney U test or Krus-
kal–Wallis test. For comparisons, based on the cutoff values
used in our laboratory, patients were further divided into 3
groups: <24mEq/L (low), 24 to 30mEq/L (normal), and
>30mEq/L (high) of TA-Bic levels.
Time to becoming anuric during the first 3 years of dialysis
therapy was estimated and compared between groups using the
cumulative incidence competing risk method and the K-sample
test developed by Gray.28 Data for switching to HD, kidney
transplantation, loss to follow-up, and death were censored in
the analysis. To determine risk factors for becoming anuric,
competing risks multivariate Cox regression was performed, as
described by Fine and Gray,29 and 3 different models were
constructed; adjustments in model 1: demographic and clinical
parameters, including age, sex, BMI, Charlson Comorbidity
Index score, sevelamer hydrochloride treatment, antihyperten-
sive medications, and peritonitis rate; model 2: model 1 plus
dialysis-specific parameters, including types of PD solutions
(type of buffers, final pH of solutions, and use of icodextrin),
prescribed dialysate volume, PD ultrafiltration, total Kt/V urea,
nPCR, and %LBM; model 3: model 2 plus laboratory
parameters, including serum hemoglobin, serum albumin, total
cholesterol, calcium, phosphorus, serum ferritin, and CRP. For
all survival analyses, the Cox model proportionality assumption
was confirmed by testing Schoenfeld residuals. First-order
interaction terms between covariates were examined for all
models, but there was no evidence of an interaction between
those covariates. The results are expressed as a hazard ratio
(HR) and 95% confidence interval (CI). We further modified the
above Cox regression analyses by using a restricted cubic spline
model with 2 degrees of freedom to illustrate systemic relations
between serum bicarbonate levels and the risk of anuric event.
This method generally examines nonlinear associations to avoid
issues caused by potential inappropriate assumptions concern-
ing linearity.30
In addition, generalized linear mixed models for repeated
measures were applied to analyze the effects of TA-Bic on the
decline in RRF over the first 3 years of dialysis treatment. The
slope of the decline in RRF over time was also calculated and
compared by a linear mixed model, and was expressed as the
estimate coefficient and 95% CI (mL/min/mo/1.73m2).
Furthermore, an additional comparison was made after adjust-
ing for all repeatedly measured covariates included in multi-
variate Cox regression analyses. A P value <0.05 was
considered statistically significant.
RESULTS
Patient Characteristics
From the total of 549 patients, we excluded 144 patients,
thus 405 patients were included in the final analysis (Figure 1).
Compared with the included patients, the excluded patients
were significantly older and more frequently had a higher
comorbidity score. Other baseline characteristics were not
different between included and excluded patients. Table 1
shows the baseline characteristics of the 405 included patients.
The mean age of the patients was 59.4 years (range, 22–85
Medicine  Volume 94, Number 31, August 2015years), 53.8% were males, and 52.1% were diabetic. The
median TA-Bic level was 26.0mEq/L (range, 16.6–
33.9mEq/L). All baseline characteristics were not different
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Baseline Characteristics of Study Subjects Stratified by Time-Averaged Serum Bicarbonate
Time-Averaged Serum Bicarbonate, mEq/L
Low (<24, n¼ 97) Normal (24–30, n¼ 264) High (>30, n¼ 44) P for trend
Age, y 59.2 14.6 59.5 13.4 59.4 14.2 0.900
Sex (male) 46 (47.4) 148 (56.1) 24 (54.5) 0.259
Body mass index, kg/m2 22.5 3.2 22.6 3.1 22.9 2.8 0.438
Presence of diabetes mellitus 49 (50.5) 138 (52.3) 24 (54.5) 0.652
Charlson Comorbidity Index score 3.1 0.9 3.1 1.0 2.8 0.9 0.334
Laboratory findings
Hemoglobin, g/dL 10.6 1.5 10.9 1.5 10.7 1.4 0.261
Serum albumin, g/dL 3.1 0.6 3.2 0.5 3.2 0.5 0.088
Serum Anion gap, mEq/L

8.7 3.1 9.1 2.8 9.0 2.6 0.419
Total cholesterol, mg/dL 181 [42–317] 181 [6–383] 181 [109–451] 0.361
Serum calcium, mg/dL 8.7 0.9 8.7 0.8 8.7 0.7 0.942
Serum phosphorus, mg/dL 4.1 1.2 4.1 1.2 4.3 1.4 0.505
Serum ferritin, ng/mL 187 [17–1693] 174 [7–1711] 157 [14–1222] 0.925
C-reactive protein, mg/dL 0.25 [0–8] 0.12 [0–36] 0.04 [0–9] 0.817
Residual GFR, mL/min/1.73m2 6.1 [1.1–17.4] 6.6 [1.1–18.8] 6.2 [1.4–12.7] 0.817
D/PCr at 4 h 0.69 0.19 0.68 0.16 0.71  0.26 0.787
nPCR, g/kg/d 0.97 0.26 0.99 0.26 0.95 0.23 0.458
Lean body mass, % body weight 61.3 14.0 64.9 14.1 62.8 11.7 0.215
PD solution profiles
Lactate-buffered 91 (93.8) 214 (81.1) 24 (54.5) <0.001
Low concentration (35mEq/L) 81 (89.0) 166 (77.6) 15 (62.5) 0.002
High concentration (40mEq/L) 10 (11.0) 48 (22.4) 9 (37.5) 0.002
Bicarbonate-bufferedy 6 (6.2) 50 (18.9) 20 (45.5) <0.001
Low pH (pH 5.5) 68 (70.1) 130 (49.2) 14 (31.8) <0.001
High pH (pH> 5.5) 29 (29.9) 134 (50.8) 30 (68.2) <0.001
Icodextrin 9 (9.3) 22 (8.3) 3 (6.8) 0.630
Dialysis characteristics
Automated PD 1 (1.0) 2 (0.8) 1 (2.3) 0.794
Prescribed dialysate volume, L/d 6.0 [4.5–8.0] 6.0 [4.5–8.0] 6.0 [4.5–8.0] 0.967
Total weekly Kt/V urea 2.6  0.9 2.7 0.8 2.5 0.6 0.897
PD ultrafiltration, mL/d 853 673 686 655 670 687 0.066
Sevelamer hydrochloride treatment 18 (18.9) 44 (17.0) 6 (14.6) 0.528
Antihypertensive medications
ACE inhibitors or ARBs 57 (58.8) 185 (70.1) 31 (70.5) 0.073
Alpha and/or beta blockers 43 (44.3) 129 (48.9) 24 (54.5) 0.251
Calcium channel blockers 57 (58.8) 161 (61.0) 27 (61.4) 0.716
Loop diuretics 42 (43.3) 116 (43.9) 24 (54.5) 0.313
Dose of furosemide, mg/d 48.3 63.0 44.2 61.0 57.3 65.9 0.665
Values for categorical variables are given as a number (percentage); values for continuous variables are given as mean standard deviation or
median [interquartile range]. ACE¼ angiotensin converting enzyme, ARB¼ angiotensin receptor blocker, D/PCr¼ dialysate/plasma creatinine ratio,
rate
Cl
e-bu
Medicine  Volume 94, Number 31, August 2015 Low Serum Bicarbonate and Residual Renal Functionamong patients with TA-Bic< 24mEq/L, 24 to 30mEq/L, and
>30mEq/L, with the exception of types of PD solutions; the
proportion of patients who were either on low (35mEq/L) or
high (40mEqL) lactate-buffered solutions and were on low pH
(5.5) solutions was significantly higher in the lower TA-Bic
group compared with the higher TA-Bic group. Conversely,
GFR¼ glomerular filtration rate, nPCR¼ normalized protein catabolic
Anion gap (AG) was calculated using the formula: AG¼Naþ  (
yBicarbonate-buffered dialysate is composed of a bicarbonate-/lactatpatients in the higher TA-Bic group were more likely to use
bicarbonate-/lactate-buffered solutions (25 and 15mEq/L,
respectively) and high pH (>5.5) solutions.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Patients were followed for a mean duration of 25.8 months.
During the follow-up period, a total of 299 episodes of perito-
nitis were observed in 171 patients (total 871.3 patient-years)
and overall peritonitis rate was 0.34 per patient-year. Mean
peritonitis rates were 0.29 (64 episodes per 221.9 patient-years),
0.37 (203 episodes per 552.9 patient-years), and 0.33 (32
, PD¼ peritoneal dialysis.
þ HCO3).
ffered solution (25/15mEq/L, respectively).episodes per 96.4 patient-years) in low, normal, and high
TA-Bic groups, respectively (P for trend¼ 0.126). In addition,
serum albumin concentration, which is usually recognized as a
www.md-journal.com | 3
FIGURE 3. The cumulative incidence curves for the time until
complete loss of residual renal function between groups based on
the level of 24mEq/L (A) and the level of <24, 24 to 30, and
Medicine  Volume 94, Number 31, August 2015nutritional and inflammatory marker, did not differ between the
groups during follow-up (3.3 0.7, 3.2 0.6, and 3.2 0.6 g/
dL in the 3 groups of TA-Bic: <24, 24–30, and >30mEq/L,
respectively; P¼ 0.859 by comparison of difference in overall
change by linear mixed models with repeated measures).
Loss of RRF
RRF was measured at least 4 times in 287 (70.9%), 5 times
in 242 (59.8%), 6 times in 209 (51.6%), and 7 times in 166
(41.0%) patients. During the first 3 years of dialysis, 95 (23.5%)
patients became anuric. The mean time until patients became
anuric was 20.8 9.0 months. The results of the cubic splines
graph illustrating the association between TA-Bic levels (in
percentiles) and the risk of anuric event are shown in Figure 2. A
trend toward increased risk of anuria was observed in PD
patients with lower TA-Bic levels. The lowest quintile of serum
TA-Bic appeared to be associated with the greatest risk of
becoming anuria.
In addition, the cumulative incidence of complete RRF
loss was significantly lower in patients with higher TA-Bic level
compared with patients with TA-Bic level <24mEq/L
(Figure 3). The HRs for full loss of RRF within 3 years after
dialysis initiation are shown in Table 2. Models with various
adjustment showed that the association between the 2 was
significant and consistent. Using serum TA-Bic as a continuous
variable, an HR for total loss of RRF was 0.84 per 1mEq/L
higher for TA-Bic (95% CI, 0.75–0.93; P¼ 0.002), indicating
that higher TA-Bic was significantly associated with decreased
risk of complete RRF loss. Moreover, patients with a TA-
Bic< 24mEq/L conferred a 2.62-fold higher risk of becoming
anuric compared with patients with a TA-Bic 24mEq/L.
Decline of RRF
We evaluated the effects of TA-Bic on the decline of RRF
over time using generalized linear mixed models for repeated
Chang et almeasures (Figure 4). The overall rates of RRF decline after the
start of PD were significantly greater in patients with TA-
Bic< 24mEq/L compared with those with TA-Bic 24mEq/L
FIGURE 2. Cubic spline regressionmodels of the log-hazard (with
95% confidence interval and 2 degrees of freedom) of anuric
event according to the percentile of time-averaged serum
bicarbonate levels. (A) Univariate model and (B) multivariate
model adjusted for age, sex, body mass index, Charlson Comor-
bidity Index score, medications (sevelamer, antihypertensive),
peritonitis rate, types of peritoneal dialysis solutions (lactate/
bicarbonate buffered solution, final pH of solution, use of icodex-
trin), dialysate volume, peritoneal dialysis ultrafiltration, total Kt/V
urea, normalized protein catabolic rate, percentage of lean body
mass, serum hemoglobin, serum albumin, total cholesterol,
calcium, phosphorus, serum ferritin, and C-reactive protein levels.
4 | www.md-journal.com(0.15 vs0.11mL/min/mo/1.73m2,P< 0.001).When patients
were divided into 3 groups of TA-Bic (<24, 24–30, and
>30mEq/L), the monthly change in RRF decline was signifi-
cantly higher in patients in the lowTA-Bic group (0.15mL/min/
mo/1.73m2) compared with those in the normal (0.11mL/min/
mo/1.73m2,P< 0.001) and the high TA-Bic (0.09mL/min/mo/
1.73m2, P< 0.001) groups, respectively. When the curvature of
GFR decline was alternatively modeled by analyzing log-trans-
formed data over the entire study period, similar results were
found (data not shown), indicating that a lower TA-Bic level was
associated with the rapid decline in RRF within 3 years after
dialysis was initiated.
Even after additional interaction terms for time with
potential confounders were included in the Cox regression
analyses, this association between the 2 remained significant
and consistent (Table 3). Furthermore, to verify whether the
results were influenced by baseline RRF, we repeated all mixed
model analyses in subgroups of patients with a high or a low
baseline RRF based on the median residual GFR level (6.41mL/
>30mEq/L (B) of TA-Bic levels. TA-Bic¼ time-averaged serum
bicarbonate.min/1.73m2). In this additional analysis, the observed effects in
the different subgroups were similar to those in the crude
analyses, and this did not alter our conclusions (data not shown).
DISCUSSION
In this study, we sought to delineate the relationship
between serum bicarbonate levels and RRF in our ESRD cohort
of patients with PD. We showed that a low TA-Bic level
independently predicted complete loss of RRF and was also
significantly associated with a rapid decline in RRF. This
finding suggests that metabolic acidosis exerts a detrimental
effect on RRF decline. Thus, correcting low bicarbonate level
can be considered as a therapeutic option to preserve RRF even
after dialysis initiation.
Although ESRD patients are treated with dialysis, previous
studies including ours have clearly showed that metabolic
acidosis is common and significantly associated with adverse
outcomes in these patients.11–16,31–34 In fact, metabolic acidosis
is reported to be an important cause of many deleterious
metabolic consequences, including protein-energy wasting,
inflammation, bone disease, and disturbance in endocrine func-
tion.31–34 Furthermore, there is evidence that indicates there is a
significant association between low serum bicarbonate levels
and increased mortality in these patients.11–16 In addition to
these unfavorable effects, metabolic acidosis has also been
highly related to kidney damage and rapid decline of GFR in
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Multivariable Cox Regression Analyses for the Risk of Complete Loss of Residual Renal Function
Model 1 Model 2 Model 3
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Continuous model
(Per 1mEq/L TA-Bic increase) 0.90 (0.83; 0.98) 0.011 0.89 (0.81; 0.97) 0.009 0.84 (0.75; 0.93) 0.002
Categorical model
(Two groups of TA-Bic)
<24mEq/L 1.95 (1.29; 2.96) 0.002 2.10 (1.35; 3.26) <0.001 2.62 (1.64; 4.19) <0.001
24mEq/L 1.00 (reference) 1.00 (reference) 1.00 (reference)
(Three groups of TA-Bic)
<24mEq/L 3.02 (1.21; 7.53) 0.018 3.08 (1.26; 7.53) 0.014 3.52 (1.49; 8.34) 0.004
24–30mEq/L 1.64 (0.67; 4.02) 0.280 1.54 (0.64; 3.71) 0.330 1.41 (0.59; 3.33) 0.440
>30mEq/L 1.00 (reference) 1.00 (reference) 1.00 (reference)
Adjustments in model 1: demographic and clinical parameters, including age, sex, body mass index, Charlson Comorbidity Index score, sevelamer
treatment, antihypertensive medications, and peritonitis rate; model 2: model 1 plus dialysis-specific parameters, including types of peritoneal dialysis
solutions (lactate/bicarbonate buffered solution, final pH of solution, use of icodextrin), dialysate volume, peritoneal dialysis ultrafiltration, total Kt/V
urea, normalized protein catabolic rate, and percentage of lean body mass; model 3: model 2 plus laboratory parameters, including serum hemoglobin,
and
Medicine  Volume 94, Number 31, August 2015 Low Serum Bicarbonate and Residual Renal Functionpatients with CKD before dialysis.35,36 These findings were
further supported by several recent clinical trials showing that
treatment of metabolic acidosis with oral alkali or base-produ-
cing fruits and vegetables decreased markers of renal injury and
attenuated progression of kidney disease in these patients.17–24
Of note, the importance of preserving RRF is well established in
patients with ESRD, and decline of RRF is a critical prognostic
factor in these patients.1–10 Moreover, we have recently shown
that a low TA-Bic is associated with increasedmortality, and the
TA-Bic level also positively correlated with RRF in the same
cohort of incident PD patients.16 These findings suggest a
possible causal link between acidosis-induced hastened decline
in RRF and adverse outcomes. Further investigations are
required to establish the direct relationship between low serum
serum albumin, total cholesterol, calcium, phosphorus, serum ferritin,
Bic¼ time-averaged serum bicarbonate.bicarbonate and loss of RRF in these patients, which can
provide a rationale for additional therapeutic strategy to
improve clinical outcomes.
FIGURE 4. Changes in residual renal function over time between
groups based on the level of 24mEq/L (A) and the level of<24, 24
to 30, and >30mEq/L (B) of TA-Bic levels. Gray lines represent
individual patient measurements, and solid and dash lines
represent predicted slopes. TA-Bic¼ time-averaged serum
bicarbonate.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Our findings deserve attention as we clarified the associ-
ation between acidosis and RRF decline using different stat-
istical methods with rigorous adjustment. In this study, we
clearly showed that low serum bicarbonate level was an inde-
pendent predictor of full loss of RRF after dialysis initiation in
the multivariate Cox proportional hazards model which
adjusted for potentially multiple confounding covariates,
including demographic, clinical, laboratory, and dialysis-
specific data. In addition, the rate of RRF decline estimated
by generalized linear mixed models for repeated measures was
significantly greater in patients with TA-Bic< 24mEq/L com-
pared with those with TA-Bic 24mEq/L. Increased RRF
decline in patients with low bicarbonate concentrations was
also confirmed when we compared the rate of RRF decline in
the 3 different groups of TA-Bic levels (<24, 24–30, and
>30mEq/L) using the same analytical method. In this regard,
our robust finding highlights the importance of acidosis as a
negative effector on RRF in PD patients even after dialysis
initiation.
The underlying mechanisms for rapid RRF decline in CKD
patients with lower serum bicarbonate levels are unclear.
However, there is compelling evidence that kidney injury is
attributed to increased ammoniogenesis in the proximal tubule
and increased production of inflammatory mediators such as
endothelin, aldosterone, and angiotensin II caused by acid
load.37–39 In particular, animal studies using a 5/6 nephrectomy
model, which is the classic experimental model for human
CKD, showed that increased ammoniogenesis-mediated tubu-
lointerstitial injury through activation of the compliment cas-
cade37 and metabolic acidosis induced decline in GFR through
endothelin A receptors.38 In addition, acid retention associated
with reduced GFR augments kidney injury through increased
kidney levels of endothelin-1, aldosterone, and angiotensin II in
C-reactive protein. CI¼ confidence interval, HR¼ hazard ratio, TA-the 2/3 nephrectomy model.39 Interestingly, all these studies
showed that alkali supplements ameliorated kidney injury,
further supporting the detrimental role of acidosis in kidney
www.md-journal.com | 5
TABLE 3. Multivariate Adjusted Linear Mixed Models for Monthly Change in Residual Renal Function (mL/min/mo/1.73m2)
Model 1 Model 2 Model 3
Estimate (95% CI) P Estimate (95% CI) P Estimate (95% CI) P
(Two groups of TA-Bic)
<24mEq/L 0.15 (0.12; 0.10) <0.001 0.15 (0.12; 0.10) <0.001 0.16 (0.12; 0.11) <0.001
24mEq/L 0.11 0.11 0.11
(Three groups of TA-Bic)
<24mEq/L 0.15 (0.16; 0.14) <0.001 0.15 (0.16; 0.14) <0.001 0.16 (0.17; 0.14) <0.001
24–30mEq/L 0.11 (0.12; 0.10) 0.287 0.11 (0.12; 0.10) 0.297 0.12 (0.13; 0.11) 0.230
>30mEq/L 0.10 (0.12; 0.07) 0.10 (0.12; 0.08) 0.10 (0.13; 0.08)
Adjustments in model 1: demographic and clinical parameters, including age, sex, body mass index, Charlson Comorbidity Index score, sevelamer
treatment, antihypertensive medications, and peritonitis rate; model 2: model 1 plus dialysis-specific parameters, including types of peritoneal dialysis
solutions (lactate/bicarbonate buffered solution, final pH of solution, use of icodextrin), dialysate volume, peritoneal dialysis ultrafiltration, total Kt/V
urea, normalized protein catabolic rate, and percentage of lean body mass; model 3: model 2 plus laboratory parameters, including serum hemoglobin,
and
Chang et al Medicine  Volume 94, Number 31, August 2015function deterioration. With such experimental-based back-
ground in mind, 6 randomized controlled trials have been
conducted to date and most of the studies showed positive
results that favor correcting acidosis in terms of preserving
kidney function.19–24 However, all study subjects were in CKD
stage 1 to 4 before dialysis, thus it is unknown whether such
beneficial effects of correcting acidosis may persist in patients
receiving dialysis. Notably, one previous study in a Chinese PD
population reported that continuous ambulatory PD patients
with normal anion gap metabolic acidosis had better RRF than
those with increased anion gap metabolic acidosis and those
without acidosis. The authors presumed that increased urinary
excretion of bicarbonate in patients with better RRF may be
responsible for the occurrence of metabolic acidosis.40 How-
ever, their findings have not been validated by other studies and
should be interpreted with caution. In fact, this study was
limited by relatively small sample size (20 continuous ambu-
latory PD patients), thus resulting in insufficient statistical
power. In addition, they did not provide multivariable-adjusted
analysis data. Moreover, their cross-sectional study captured
only one measurement of each parameter at a specific time
point, thus could not represent the whole dialysis period. In
contrast, we presented TA-Bic levels and residual GFR using
longitudinal follow-up data, and provided convincing associ-
ation between bicarbonate level and RRF with rigorous adjust-
ment. In this regard, our findings call for well-designed
randomized controlled trials with alkali therapy or its altern-
atives to quantify the causal effect of low serum bicarbonate on
reduced GFR and to provide complimentary or adjunctive
therapies for preserving RRF in patients with ESRD on dialysis.
Optimal bicarbonate level has not yet been determined in
PD patients. Our prior work showed that mortality risk was the
lowest in PD patients with TA-Bic 24mEq/L.16 In line with
this finding, the present study also showed that decline in
residual GFR was slower in those with bicarbonate levels
24mEq/L. The threshold level based on our studies is slightly
higher than the bicarbonate level recommended by the National
Kidney Foundation Disease Outcomes Quality Initiative.41
serum albumin, total cholesterol, calcium, phosphorus, serum ferritin,
serum bicarbonate.However, the suggested cutoff value was merely based on
the effects of acidosis on metabolic bone disease and nutritional
parameters.41 Interestingly, post hoc analysis of the African
6 | www.md-journal.comAmerican Study of Kidney Disease and Hypertension (AASK)
trial showed that higher levels of serum bicarbonate
(25mmol/L) within the normal range were associated with
better survival and kidney outcomes. Moreover, the guidelines
from the United Kingdom Renal Association suggest a higher
threshold of bicarbonate in PD patients than in HD
patients.42,43 Thus, future works should address this issue on
whether PD patients will benefit from higher target of
bicarbonate level.
There were several limitations to this present study. As
aforementioned, this is an observational study with a relatively
small sample size. Hence, the causality of our findings needs
further confirmation. In fact, metabolic acidosis can be merely a
secondary phenomenon as kidney function declines because it
generally occurs due to a loss of buffer capacity by the kidney.
However, acidotic milieu itself can cause tubular injury and
activate the inflammatory process, thus it is very likely that
kidney failure and acidosis work together in a vicious cycle and
ultimately result in exacerbation of kidney injury. In addition,
considering that the mechanism contributing to RRF decline is
multifactorial,1–3 lack of information to further explain loss of
RRF in these patients is another drawback. Data representing
overall volume status (body weight changes, dietary water
intake, and a bioelectrical impedance analysis) and nutritional
status (subjective global assessment, anthropometry, and
dietary protein intake) were not available for analysis. Other
information related to worsening RRF, such as use of nephro-
toxic agents or history of infection, was not included. Despite
these limitations, this study showed that a low TA-Bic level
independently predicted full loss of RRF during the first 3 years
of dialysis, and was significantly associated with rapid
decline of RRF in PD patients, even after extensive adjustment
for demographic, clinical, laboratory, and dialysis-specific
covariates.
In conclusion, this study showed a clear association
between low serum bicarbonate and loss of RRF in PD patients.
However, it has not been determined whether correction of
metabolic acidosis for this indication provides additional pro-
C-reactive protein. CI¼ confidence interval, TA-Bic¼ time-averagedtection for preserving RRF in these patients. Therefore, future
interventional studies should more appropriately address
this question.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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